In a few months, the U.S. Supreme Court will decide a closely watched case that could lead to patents being canceled more easily and, therefore, chill deals that small drug makers may pursue in hopes of finding larger partners to get their medicines to market.

The case turns on disputed language in U.S. patent law, which was overhauled in 2011, that prohibits a company from patenting an invention if it was for sale for more than a year before filing a patent application. The court, which heard oral arguments on Tuesday, must decide whether Congress intended the law to apply only to agreements that are publicly known or also encompasses confidential transactions out of the public eye.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • So much innovation happens from smaller players. I believe it’s crucial we protect their ability to secure strong IP rights. And if you look at changes AIA made (e.g. 35 USC 102(c)), seems the lawmakers already want to protect confidential agreements/joint research agreements/etc (at least to some degree). I may be extrapolating here a bit but Supreme Court should extend a similar notion in this case IMO.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy